BerGenBio Management
Management criteria checks 1/4
BerGenBio's CEO is Martin Olin, appointed in Sep 2021, has a tenure of 2.42 years. total yearly compensation is NOK10.97M, comprised of 44.7% salary and 55.3% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $65.65K. The average tenure of the management team and the board of directors is 2.3 years and 1.5 years respectively.
Key information
Martin Olin
Chief executive officer
NOK 11.0m
Total compensation
| CEO salary percentage | 44.7% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -NOK 190m |
| Sep 30 2023 | n/a | n/a | -NOK 226m |
| Jun 30 2023 | n/a | n/a | -NOK 258m |
| Mar 31 2023 | n/a | n/a | -NOK 293m |
| Dec 31 2022 | NOK 11m | NOK 5m | -NOK 302m |
| Sep 30 2022 | n/a | n/a | -NOK 294m |
| Jun 30 2022 | n/a | n/a | -NOK 304m |
| Mar 31 2022 | n/a | n/a | -NOK 309m |
| Dec 31 2021 | NOK 4m | NOK 1m | -NOK 309m |
Compensation vs Market: Martin's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD668.03K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
CEO
Martin Olin (54 yo)
2.4yrs
Tenure
NOK 10,966,129
Compensation
Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.4yrs | NOK 10.97m | 0.11% $ 65.7k | |
| Chief Financial Officer | 5.9yrs | NOK 2.85m | 0.014% $ 8.4k | |
| Chief Business Officer | 2.3yrs | NOK 3.39m | no data | |
| Chief Medical Officer | 1.8yrs | NOK 390.51k | no data | |
| Head of IR | no data | no data | no data | |
| Medical Director | no data | no data | no data |
2.3yrs
Average Tenure
54yo
Average Age
Experienced Management: BRRG.F's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Non-Executive Director | 3.2yrs | NOK 378.00k | 0.018% $ 10.2k | |
| Independent Non-Executive Director | 13.4yrs | NOK 345.00k | 0.11% $ 64.9k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Non-Executive Director | 4.9yrs | NOK 353.00k | 0.017% $ 10.1k | |
| Independent Chairman of the Board | 2.1yrs | NOK 1.12m | 0.081% $ 46.8k | |
| Member Scientific Advisory Board | less than a year | no data | no data |
1.5yrs
Average Tenure
62yo
Average Age
Experienced Board: BRRG.F's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/26 19:47 |
| End of Day Share Price | 2023/11/29 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BerGenBio ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Geir Holom | DNB Markets |